2.40
7.01%
-0.1808
시간 외 거래:
2.47
0.07
+2.92%
Incannex Healthcare Inc 주식(IXHL)의 최신 뉴스
Incannex Healthcare names Lou Barbato as chief medical officer - MSN
Incannex appoints new chief medical officer - Investing.com India
Incannex appoints new chief medical officer By Investing.com - Investing.com South Africa
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer - GlobeNewswire
Incannex Healthcare Appoints Dr. Barbato as CMO - TipRanks
Incannex Healthcare Leads The Charge On US Penny Stocks With 2 Other Notable Picks - Simply Wall St
Incannex Healthcare secures $3.3 million through debt financing By Investing.com - Investing.com Australia
Incannex Healthcare secures $3.3 million through debt financing - Investing.com
Incannex Healthcare secures A$6.9 million funding By Investing.com - Investing.com Australia
Incannex Healthcare secures A$6.9 million funding - Investing.com
Incannex Provides Business Updates and Progress on OSA Drug Candidate in Phase 2/3 Trials - Sleep Review
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL) - Invezz
R&D tax breaks buoy Incannex as losses narrow - Green Market Report
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Significant Growth in Short Interest - Defense World
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates - The Manila Times
Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Update - MarketBeat
Incannex Secures Up to $60M in Financing to Support Clinical Trials - Sleep Review
Incannex secures financing deal valued at US$60 million - Mugglehead
Incannex $60 Million Deal With Arena For Late-Stage Drug TrialsIncannex Healthcare (NASDAQ:IXHL) - Benzinga
Incannex Healthcare secures $60 million funding via equity and debt - Investing.com
Incannex Healthcare secures $60 million funding via equity and debt By Investing.com - Investing.com UK
Incannex Healthcare lands $60 million financing deal - Green Market Report
Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors - GlobeNewswire
Incannex secures $60 million in funding for clinical trials - Investing.com
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Large Growth in Short Interest - MarketBeat
Thinking about buying stock in Altimmune, UiPath, Incannex Healt - GuruFocus.com
Virtu Financial LLC Buys New Shares in Incannex Healthcare Inc. (NASDAQ:IXHL) - Defense World
4 Psychedelic Stocks to Consider as Clinical Trials Heat up - Investing.com
FDA Review of PsiGAD2 IND complete; clinical trial for - GlobeNewswire
FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety - Benzinga
Incannex Healthcare gets FDA nod for Phase 2 trial - Green Market Report
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed - StockTitan
Tidal Investments LLC Buys New Stake in Incannex Healthcare Inc. (NASDAQ:IXHL) - MarketBeat
Tidal Investments LLC Acquires Shares of 423,410 Incannex Healthcare Inc. (NASDAQ:IXHL) - Defense World
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X - GlobeNewswire
Head to Head Review: Zai Lab (NASDAQ:ZLAB) vs. Incannex Healthcare (NASDAQ:IXHL) - Defense World
Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Down 69.0% in June - MarketBeat
7 Best Psychedelic Stocks in 2024 | Investing - U.S News & World Report Money
Patient Dosing Begins in Phase 2/3 Trial for OSA Drug Candidate IHL-42X - Sleep Review
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea - Yahoo Finance
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder - Yahoo Finance
'Truly Remarkable’ Results Spur Incannex's Phase 2/3 Trials for Sleep Apnea Drug Candidate, Says CEO - Sleep Review
자본화:
|
볼륨(24시간):